潘多鲁姆科技公司筹集了1800万美元用于开发外体治疗,其中一种主要药物获得了美国罕见眼病孤儿药物地位. Pandorum Technologies raised $18M to develop exosome therapies, with a lead drug gaining U.S. orphan drug status for rare eye diseases.

Pandorum Technology是一家以孟加拉为基地的生物技术公司,已经筹集了1 800万美元的B系列资金,用于推进其基于异体的再生疗法,其主要候选人Kuragenx因罕见眼疾接受美国林业发展局孤儿药物称号。 Pandorum Technologies, a Bengaluru-based biotech firm, has raised $18 million in Series B funding to advance its exosome-based regenerative therapies, with its lead candidate Kuragenx receiving U.S. FDA Orphan Drug Designation for rare eye diseases. 该公司由Tuhin Bhowmick和Arun Chandru创办,正在扩大与欧洲、亚太合作伙伴的全球制造网络,并探索中东的合作。 The company, founded by Tuhin Bhowmick and Arun Chandru, is expanding its global manufacturing network with partners in Europe, Asia-Pacific, and exploring Middle East collaborations. 它旨在扩大其平台,治疗影响肺部、肝脏和神经系统的系统状况。 It aims to extend its platform to treat systemic conditions affecting the lungs, liver, and nervous system.